Elspeth McIntosh began her career in the pharmaceutical industry in 1993, initially working in clinical research, before moving into Pharmacovigilance. She has extensive experience of all aspects of pharmacovigilance and has been a small company QPPV since 1999, dealing with innovative, generic and biotech/biological products. Elspeth set up Castle Pharmacovigilance in 2009 and post Brexit she is a UK QPPV and UK National Contact Person for several small pharma companies and provides general PV support to a wide range of pharma companies.

ANNA-SHARI MELIN is a life sciences lawyer and German Rechtsanwältin. Her practice encompasses a broad range of EU and German regulatory and compliance matters affecting pharmaceutical, biotechnology and medical device companies as well as food, cosmetics, consumer goods and digital health companies. Anna-Shari advises clients throughout the product life cycle including analyses and strategy/risk assessments in relation to clinical trials, GMP compliance, early access programs and market access, pharmacovigilance, medicinal product shortages, recalls, and compliance. Clients benefit from Anna-Shari’s EU and German law practice, in which she brings valuable perspective at the intersection of European and German national law.

Magnus Ysander is the EU and UK QPPV for the AstraZeneca group of companies since 2015 and is based in Gothenburg, Sweden. He joined the company in 2002 and have had several specialist, oversight and line managerial roles within the AstraZeneca pharmacovigilance organisation. Magnus is a MD and has previously worked as a certified Orthopedic Surgeon. He is a member of EFPIA Pharmacovigilance Expert Group and the Program Committee for the DIA QPPV Forum.